Tags

Type your tag names separated by a space and hit enter

Antibodies to malondialdehyde oxidized low-density lipoproteins predict long term cardiovascular mortality in high risk patients.
Int J Cardiol. 2013 Sep 20; 168(1):484-9.IJ

Abstract

AIMS

Antibodies to oxidized low-density lipoproteins (oxLDLAbs) are detectable in the serum of patients with and without atherosclerosis, but it is unclear if they play a pathogenic or a protective role in atherogenesis or if they are simply a marker of atherosclerosis. Therefore, in a prospective cohort study we investigated if oxLDLAbs titer predicts cardiovascular (CV) events in high-risk coronary artery disease patients.

METHODS AND RESULTS

The titer of IgG antibodies to malondialdehyde modified oxidized low-density lipoproteins was measured in 748 randomly selected patients of the GENICA study who underwent coronary angiography and assessment of incident CV events at follow-up. Patients were classified by oxLDLAbs into a low and a high titer group, corresponding to the first three and the last quartile, respectively. Cardiovascular event-free survival was compared between oxLDLAbs groups by Kaplan-Meier and multivariate technique including propensity score matching analysis. During long-term follow-up (median 7.2 years) CV deaths were observed in 65 patients (11.6%), more commonly in the high than in the low oxLDLAbs group (patients free from CV death 83.1% vs. 89% respectively, p=0.025). The incidence of CV events was also higher in the former than in latter (event-free survival 69.2% vs. 77.7% respectively, p=0.030).

CONCLUSIONS

An oxLDLAbs titer above the 75th percentile is a marker of LDL oxidation which predicts a worse CV prognosis at long term follow-up in high-risk Caucasian patients referred for coronary angiography.

Authors+Show Affiliations

Dept. of Medicine-Internal Medicine University of Padua, Italy.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

23102599

Citation

Maiolino, Giuseppe, et al. "Antibodies to Malondialdehyde Oxidized Low-density Lipoproteins Predict Long Term Cardiovascular Mortality in High Risk Patients." International Journal of Cardiology, vol. 168, no. 1, 2013, pp. 484-9.
Maiolino G, Pedon L, Cesari M, et al. Antibodies to malondialdehyde oxidized low-density lipoproteins predict long term cardiovascular mortality in high risk patients. Int J Cardiol. 2013;168(1):484-9.
Maiolino, G., Pedon, L., Cesari, M., Frigo, A. C., Barisa, M., Rossitto, G., Seccia, T. M., Zanchetta, M., & Rossi, G. P. (2013). Antibodies to malondialdehyde oxidized low-density lipoproteins predict long term cardiovascular mortality in high risk patients. International Journal of Cardiology, 168(1), 484-9. https://doi.org/10.1016/j.ijcard.2012.09.165
Maiolino G, et al. Antibodies to Malondialdehyde Oxidized Low-density Lipoproteins Predict Long Term Cardiovascular Mortality in High Risk Patients. Int J Cardiol. 2013 Sep 20;168(1):484-9. PubMed PMID: 23102599.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Antibodies to malondialdehyde oxidized low-density lipoproteins predict long term cardiovascular mortality in high risk patients. AU - Maiolino,Giuseppe, AU - Pedon,Luigi, AU - Cesari,Maurizio, AU - Frigo,Anna Chiara, AU - Barisa,Marlena, AU - Rossitto,Giacomo, AU - Seccia,Teresa Maria, AU - Zanchetta,Mario, AU - Rossi,Gian Paolo, Y1 - 2012/10/25/ PY - 2012/05/03/received PY - 2012/09/03/revised PY - 2012/09/25/accepted PY - 2012/10/30/entrez PY - 2012/10/30/pubmed PY - 2014/5/7/medline KW - Anti-LDL-oxidized antibodies KW - Atherosclerosis KW - BP KW - CAD KW - Coronary artery disease KW - HDL KW - LDL KW - MDA KW - MI KW - OxLDL KW - OxLDLAbs KW - Prognosis KW - antibodies anti-oxidized low density lipoprotein KW - blood pressure KW - coronary artery disease KW - high-density lipoprotein KW - low density lipoprotein KW - malondialdehyde KW - myocardial infarction KW - oxidized low density lipoprotein SP - 484 EP - 9 JF - International journal of cardiology JO - Int. J. Cardiol. VL - 168 IS - 1 N2 - AIMS: Antibodies to oxidized low-density lipoproteins (oxLDLAbs) are detectable in the serum of patients with and without atherosclerosis, but it is unclear if they play a pathogenic or a protective role in atherogenesis or if they are simply a marker of atherosclerosis. Therefore, in a prospective cohort study we investigated if oxLDLAbs titer predicts cardiovascular (CV) events in high-risk coronary artery disease patients. METHODS AND RESULTS: The titer of IgG antibodies to malondialdehyde modified oxidized low-density lipoproteins was measured in 748 randomly selected patients of the GENICA study who underwent coronary angiography and assessment of incident CV events at follow-up. Patients were classified by oxLDLAbs into a low and a high titer group, corresponding to the first three and the last quartile, respectively. Cardiovascular event-free survival was compared between oxLDLAbs groups by Kaplan-Meier and multivariate technique including propensity score matching analysis. During long-term follow-up (median 7.2 years) CV deaths were observed in 65 patients (11.6%), more commonly in the high than in the low oxLDLAbs group (patients free from CV death 83.1% vs. 89% respectively, p=0.025). The incidence of CV events was also higher in the former than in latter (event-free survival 69.2% vs. 77.7% respectively, p=0.030). CONCLUSIONS: An oxLDLAbs titer above the 75th percentile is a marker of LDL oxidation which predicts a worse CV prognosis at long term follow-up in high-risk Caucasian patients referred for coronary angiography. SN - 1874-1754 UR - https://www.unboundmedicine.com/medline/citation/23102599/Antibodies_to_malondialdehyde_oxidized_low_density_lipoproteins_predict_long_term_cardiovascular_mortality_in_high_risk_patients_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0167-5273(12)01286-7 DB - PRIME DP - Unbound Medicine ER -